Antitumor activity and mechanism of resistance of the novel HDAC and PI3K dual inhibitor CUDC-907 in pancreatic cancer.

Shuang LiuShoujing ZhaoYang DongTingting WangXiaojia NiuLijing ZhaoGuan Wang

Published in: Cancer chemotherapy and pharmacology (2021)

Taken together, these findings support the clinical development of CUDC-907 for the treatment of pancreatic cancer and identify compensatory activation of mTOR and MEK/ERK as a possible mechanism of resistance to CUDC-907.

Keyphrases

cell proliferation
pi k akt
signaling pathway
combination therapy